GLP-1 weight-loss drugs
Coverage of GLP-1 weight-loss drugs in the Nexus archive.
- How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Danish company Novo Nordisk developed a highly lucrative GLP-1 weight-loss drug but lost market dominance to American rival Eli Lilly. The article questions Europe's ability to compete in the global economy as Eli Lilly outmaneuvered Novo Nordisk in the diet-drug market.
- Doctors' fears over long-term Ozempic use: DR SHEILA sounds the alarm over GLP-1 weight-loss drugs for young patients
Doctors, including DR SHEILA, are raising concerns about the long-term use of Ozempic, a GLP-1 weight-loss drug, particularly its effects on young patients.
- How ‘Ozempic face’ is pushing Gen X, already the biggest Botox and filler consumers, to the facelift table a decade early
Gen X, already leading Botox and filler use, is increasingly opting for facelifts a decade earlier due to 'Ozempic face' caused by GLP-1 weight-loss drugs, which accelerate facial aging through volume loss and sagging. Surgeons report a 50% rise in fat-grafting procedures in 2024 linked to this trend, with Gen X patients in their 40s and 50s now seeking surgical treatments typically reserved for older age groups.
- Weight loss drugs GLP-1s are shifting fashion and food trends
The rising use of GLP-1 weight-loss drugs is influencing fashion and food industries, with clothing brands adjusting designs for body fluctuations and wedding retailers requiring size waivers. An HSBC report warns reduced food expenditures could cut consumer spending by 7% in regions with high obesity rates like Eastern Europe, Latin America, and the US.
- AI scans 400,000 Reddit posts and finds hidden Ozempic side effects
Researchers analyzed 400,000 Reddit posts and found that users of GLP-1 weight-loss drugs like Ozempic frequently reported unexpected side effects such as menstrual irregularities, chills, and hot flashes. The study highlights AI's potential to use social media as an early-warning system for identifying overlooked drug side effects.
- The dark side of weight loss drugs: Ozempic's surprising hidden cost
GLP-1 weight-loss drugs like Ozempic and Wegovy may lead to judgment due to perceptions of being an 'easy way out'. People who lose weight using these medications face stigma rooted in societal expectations. This stigma creates a double bind where individuals are judged for their weight and how they manage it.
- "Ozempic breath" is boosting Hershey's sales of mints and gum
Hershey is experiencing increased sales of mints and gum due to 'Ozempic breath,' a side effect of GLP-1 weight-loss drugs that has led consumers to opt for breath-freshening products while reducing overall snacking.